Initial treatment for @entity1071 ( @entity1071 ) usually involves discontinuation of immunosuppressants. Anti- @entity2225 monoclonal antibody and/or antivirals are typically employed for persistent disease. Chemotherapy is generally reserved as a final option. The role of radiation therapy, and doses required, have not been well established. Low-dose involved field radiation therapy was used in three pediatric bone marrow transplant (BMT) @entity1 with biopsy-proven @entity1071 . One @entity1 received a matched T-cell-depleted BMT for @entity7063 . Two @entity1 with @entity3052 received an unrelated umbilical cord blood transplant, and a matched-related allogeneic BMT. All @entity1 required intubation for @entity649 due to @entity1071 . Initial treatment was discontinuation or decrease in @entity1140 . Anti- @entity2225 antibody was started in all @entity1 , and foscarnet in one @entity1 . All @entity1 were treated with three 150-cGy fractions, for a total dose of 450 cGy. Time from BMT to development of @entity1071 was 4, 2, and 32 months, respectively. Duration of observation on initial medical therapy prior to irradiation was 11 days, 12 days, and 1 day, respectively. The radiation was well tolerated with no acute complications. Two @entity1 were extubated at 8 and 4 days postradiation, respectively. The first @entity1 had complete radiographic resolution of the mass and @entity3018 at 4 months after radiation. The second died of @entity548 and @entity281 , but had significant regression of disease in the irradiated area 15 days after radiation. The third had pronounced shrinkage of his mediastinal mass. A biopsy was taken of a persistent mass 4 months after radiation, with no evidence of @entity1071 . These cases demonstrate that low-dose radiation for @entity1071 is effective for palliation and produces a durable response with no acute @entity137 .

Low-dose radiation for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['posttransplant lymphoproliferative disorder', 'PTLD', 'lymphoproliferative disease'] @entity3018 :: ('MESH:D009377', 'Disease') :: ['adenopathy'] @entity548 :: ('MESH:D006470', 'Disease') :: ['pulmonary hemorrhage'] @entity7063 :: ('MESH:D019871', 'Disease') :: ['dyskeratosis congenita'] @entity649 :: ('MESH:D012128', 'Disease') :: ['respiratory distress'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia'] @entity281 :: ('MESH:D007239', 'Disease') :: ['disseminated aspergillosis infection'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['FK-506']
@entity1071 :: (MESH:D008232,Disease) :: ['posttransplant lymphoproliferative disorder']
